Rufinamide: a double-blind, placebo-controlled proof of principle trial in patients with epilepsy (Q31871000)

4 July 2017

title

Rufinamide: a double-blind, placebo-controlled proof of principle trial in patients with epilepsy (English)

1 reference

4 July 2017

0 references

S Pålhagen

1

1 reference

4 July 2017

R Canger

2

1 reference

4 July 2017

O Henriksen

3

1 reference

4 July 2017

J A van Parys

4

1 reference

4 July 2017

M E Rivière

5

1 reference

4 July 2017

M A Karolchyk

6

1 reference

4 July 2017

publication date

1 February 2001

1 reference

4 July 2017

1 reference

4 July 2017

volume

43

1 reference

4 July 2017

issue

2

1 reference

4 July 2017

page(s)

115-124

1 reference

Intra- and inter-subject variabilities of CGP 33101 after replicate single oral doses of two 200-mg tablets and 400-mg suspension

4 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900185-6

7 January 2021

Considerations on designing clinical trials to evaluate the place of new antiepileptic drugs in the treatment of newly diagnosed and chronic patients with epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900185-6

7 January 2021

Prototype antiepileptic drug clinical development plan

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900185-6

7 January 2021

Pharmacokinetic interactions between antiepileptic drugs. Clinical considerations

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900185-6

7 January 2021

Gabapentin as add-on therapy in refractory partial epilepsy: a double-blind, placebo-controlled, parallel-group study. The US Gabapentin Study Group No. 5

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2800%2900185-6

7 January 2021

10.1016/S0920-1211(00)00185-6

Identifiers

DOI

1 reference

4 July 2017

1 reference